AdvanCell to participate in Jefferies Global Healthcare Conference in London
AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, will attend theJefferies Global Healthcare ConferenceinLondon from 17 to 20 November 2025.
The AdvanCell team – Andrew Adamovich (CEO),Anna Karmann (CMO), Matthew Vincent (CBO), Simon Puttick (CSO) and Dayle Hogg (COO) - will discuss the company’s clinical and corporate progress, including the encouraging Phase 1b trial results for 212Pb-ADVC001, recently presented at ESMO, as well as the upcoming Phase 2 expansion in metastatic castration-resistant (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC), and progress on the company’s US expansion.
“It’s an incredibly exciting time for AdvanCell,” said Andrew Adamovich, CEO of AdvanCell. “We are very encouraged by the promising Phase 1 data for ADVC001. We are expanding our US operations and manufacturing capabilities to support the next stage of development for our company, our lead asset and our pipeline. We look forward to engaging with investors and partners in London to discuss these important developments.”
About 212Pb-ADVC001
212Pb-ADVC001 is a proprietary and patented PSMA-targeting radioligand with optimized physicochemical properties and labelled with 212Pb, an alpha-emitting payload (radionuclide) with a high dose rate, 10.6 hour half-life and simple decay scheme. 212Pb-ADVC001 is designed to deliver radiation at a cellular level to effectively kill prostate cancer cells while minimizing toxicity.
212Pb-ADVC001 is being evaluated in the TheraPb trial (NCT05720130) – a prospective, open-label Phase 1/2 dose-escalation and expansion study to assess the efficacy and safety of 212Pb-ADVC001 in men with prostate cancer.
The Phase 1b dose escalation showed a compelling therapeutic index for 212Pb-ADVC001, demonstrating encouraging safety and promising anti-tumor activity, including no dose-limiting toxicities or treatment-related serious adverse events, 80% PSA50 response at doses ≥ 160 MBq and 100% objective response rate (ORR) in patients with RECIST-measurable lesions, including two complete responses (see results presented at ESMO 2025 here).
Phase 2 will utilize a randomized dose-response design and adaptive dosing elements to evaluate optimal dosing strategies of 212Pb-ADVC001 in PSMA-positive mCRPC and in mHSPC.
About AdvanCell
AdvanCell is a vertically integrated, clinical-stage radiopharmaceutical company dedicated to developing innovative cancer therapies that harness the power of targeted alpha-emitting radionuclides. By leveraging its proprietary Lead-212 platform, advanced and scalable manufacturing capabilities and world-class clinical development capabilities, AdvanCell aims to deliver novel treatments that improve outcomes for patients with cancer globally. For more information, visit www.advancell.com.au and follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251111303258/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Xsolla and Airbridge Partner to Deliver Unified Mobile and Web Performance Insights for Game Developers11.11.2025 15:36:00 CET | Press release
A New S2S Integration Connects Mobile and Web Data, Empowering Developers with a Unified View of Player Value and Marketing Performance Xsolla, a global commerce company helping developers launch, grow, and monetize their games, today announced a new mobile-focused Server-to-Server (S2S) integration with Airbridge, a leading unified measurement platform for mobile marketers. This strategic partnership empowers mobile game developers with precise, cross-platform performance tracking by bridging the gap between mobile marketing efforts and purchases made through the Xsolla Web Shop. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111170674/en/ (Graphic: Xsolla) As more developers turn to Web Shops to drive direct-to-consumer monetization beyond traditional app stores, understanding the full value of those off-platform transactions has become increasingly critical. With Xsolla’s new S2S integration, powered by Airbridge, deve
ThreatDown Launches Nexus Partner Program, Strengthening its Channel-First Commitment11.11.2025 15:02:00 CET | Press release
New program marks a strategic investment, putting partners at the center of ThreatDown’s growth strategy ThreatDown, the corporate business unit of Malwarebytes, today announced the launch of the Nexus Partner Program, a comprehensive initiative that puts partners at the center by strengthening collaboration and creating new growth opportunities for its global network of partners. The program aligns incentives, simplifies enablement, and strengthens collaboration to ensure every reseller has the resources and support needed to deliver smarter, stronger security outcomes for customers. “At ThreatDown, being channel-first means putting our partners at the center of everything we do,” says Kendra Krause, General Manager of ThreatDown. “The Nexus Partner Program reflects that belief – the program is built to equip partners with the tools they need to succeed in a rapidly evolving cybersecurity market. When our partners win, we win.” Available globally, the program offers competitive discou
Blue Matter Enhances Twine™ Platform Capabilities in Response to Growing Demand11.11.2025 15:01:00 CET | Press release
Blue Matter today announced the expansion of its Twine™ data platform’s capabilities in response to accelerating demand from biopharma companies. Enhancements include thoughtful use of artificial intelligence (AI) for advanced analytics and narratives, expanded data source integrations, master data management, and broader deployment across oncology and specialty therapeutic areas. Twine™ is Blue Matter's purpose-built customer intelligence platform for healthcare and life sciences companies. It transforms complex data from disparate sources including specialty pharmacy networks, hub services, claims databases, and other third party data sources into actionable insights that drive commercial strategy and operational excellence. With generative AI at its core, Twine helps companies more effectively acquire, master, validate, and analyze data from internal and third-party sources. Persona-specific outputs enable faster, more informed decision-making. According to Deepak Gopinath, Partner
Financial Sector Signals Rising Investment in Identity Verification11.11.2025 15:00:00 CET | Press release
Banks, fintechs, and crypto platforms are ramping up investment in fraud prevention and identity verification (IDV), positioning it as the next layer of cyber defense. According to Regula’s global survey, The Future of Identity Verification: 5 Threats and 5 Opportunities, banks are leading this trend: the share of institutions intending to increase IDV budgets by more than 50% is nearly tripling—from 4.4% to 15% in just two years. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111008888/en/ Banks lead the IDV investment surge, but fintech, crypto, and aviation sectors are catching up fast, with roughly one in six companies planning to expand IDV budgets by more than 50%. Even healthcare is joining the trend, signaling how essential verification has become beyond finance. Moderate increases in identity verification budgets are becoming common across all financial services. Roughly a third of banks and crypto firms and a fi
Ben Mauro Announces Early Deluxe Hardcover Release of HUXLEY: The Oracle, Featuring Exclusive Art From Top Sci-Fi Artists11.11.2025 15:00:00 CET | Press release
Acclaimed concept artist and worldbuilder Ben Mauro (Halo Infinite, Call of Duty, Elysium, The Predator) is excited to announce the early shipping of the deluxe hardcover edition of HUXLEY: The Oracle, the first major prequel book in the expanding HUXLEY universe. These premium deluxe editions are shipping now in limited quantities, ahead of the worldwide release of the standard edition on December 2. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251111345993/en/ Screenshot from HUXLEY: THE ORACLE The Oracle explores the origins of FURY-7, a scorched desert world ruled by the ancient machine empire known as the Oracles. The story follows Max, an elite Ronin enforcer, as he uncovers a conspiracy that sets the foundation for the events of the original HUXLEY graphic novels. This deluxe edition features over 100 color illustrations from leading industry artists, including Steve Chinhsuan Wang (Gears of War 5), Nikolas Gekko (H
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom